Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation After Liver Transplantation
Launched by UNIVERSITY OF ROMA LA SAPIENZA · Jul 26, 2017
Trial Information
Current as of June 15, 2025
Completed
Keywords
ClinConnect Summary
Protocol
1. Introduction:
Sarcopenia, a condition of skeletal muscle mass depletion and reduction of muscle strength, is the most important aspect of malnutrition secondary to liver cirrhosis. Sarcopenia is recognized to be an independent factor of morbidity and mortality befor and after liver transplantation. The prevalence of sarcopenia in liver transplanted patients has been reported to vary between 40% and 76%. Sarcopenia in hepatic cirrhosis occurs as a result of an increase in proteolysis or a reduction in protein synthesis, or a combination of the two mechanisms. The alterations...
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Liver transplantation
- Exclusion Criteria:
- • 1. Multiple organ transplantation
- • 2. Low compliance
About University Of Roma La Sapienza
The University of Roma La Sapienza, one of Italy's premier research institutions, is dedicated to advancing medical science and improving patient outcomes through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university harnesses its extensive expertise in diverse fields, including medicine, biotechnology, and public health, to conduct rigorous and ethically sound research. Committed to fostering educational excellence and promoting groundbreaking discoveries, La Sapienza actively engages in clinical trials that aim to address critical health challenges and contribute to the development of new therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rome, , Italy
Patients applied
Trial Officials
Manuela Merli, Prof
Principal Investigator
University of Roma La Sapienza
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials